RECENT
DEVELOPMENTS
IN THE
SYNTHESIS AND
APPLICATIONS
OF PYRIDINES

# RECENT DEVELOPMENTS IN THE SYNTHESIS AND APPLICATIONS OF PYRIDINES

Edited by

# Parvesh Singh

School of Chemistry and Physics, University of KwaZulu-Natal, Durban, South Africa



## Elsevier

Radarweg 29, PO Box 211, 1000 AE Amsterdam, Netherlands The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, United Kingdom 50 Hampshire Street, 5th Floor, Cambridge, MA 02139, United States

Copyright © 2023 Elsevier Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: www.elsevier.com/permissions.

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

### **Notices**

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

ISBN: 978-0-323-91221-1

For Information on all Elsevier publications visit our website at https://www.elsevier.com/books-and-journals

Publisher: Susan Dennis

Acquisitions Editor: Gabriela Capille

Editorial Project Manager: Czarina Mae Osuyos Production Project Manager: Bharatwaj Varatharajan

Cover Designer: Christian J. Bilbow

Typeset by Aptara, New Delhi, India



# Contents

Contributors	XV
Preface	xix
1. Role of pyridine and its privileged derivatives as anti-infective	ve agents
Pankaj Sharma, Vaishali Suthar, Meenu Aggarwal, Rajeev Sing and K. Poonam Kumar	9
runan orana runan	
1.1 Introduction to infectious diseases	1
1.1.1 Origin/sources of human diseases	5
1.1.2 Stages of endemic human diseases	5
1.1.3 Favorable conditions responsible for infectious diseases	8
1.1.4 Re-emergence of infectious diseases	8
1.1.5 Antimicrobial resistance	9
1.2 Anti-infective agents	9
1.3 Pyridine & its derivatives	11
1.4 Synthesis of pyridine derivatives	20
1.5 Bioisosteres and pyridine bioisosterism	25
1.5.1 General classification of bioisosteres	28
1.5.2 Classification of bioisosteres based on functional group	30
1.5.3 Few examples of bioisosterism in drug design are given below	30
1.6 Conclusion	38
Acknowledgment	39
References	39
2. Pyridine-based polymers and derivatives: Synthesis and appl	ications
Shagun Varshney and Nidhi Mishra	
2.1 Introduction	43
2.1.1 History of pyridines	44
2.1.2 Ligand properties of pyridine	45
2.1.3 Transition metal complexes of pyridine	46
2.1.4 The pharmacological activity of pyridines	47
2.2 Properties of pyridine	48
2.2.1 Physical properties	48
2.2.2 Chemical properties	49
2.3 Pyridine-based polymers of heterocyclic compounds	52
2.4 Polymers of pyridine	52
2.5 Vinyl pyridine-based polymers	53
2.5.1 Polyvinyl pyridine-based polymers in light-emitting devices	54
2.5.2 Applications in metal ion adsorption	54

vi Contents
-------------

2.6 Applications of pyridine-based polymers	58
2.6.1 Ion-exchange resins	59
2.6.2 Photoresists	59
2.6.3 Heat-resisting materials	59 50
2.6.4 High-temperature electrolyte membranes	59
2.6.5 Redox polymers	60 62
2.6.6 Biological applications 2.7 Conclusions	66
References	66
References	00
3. Synthetic strategies of functionalized pyridines and their therapeutic potential as multifunctional anti-Alzheimer's agents	
Jeelan Basha Shaik, Mohammad Khaja Mohinuddin Pinjari, Damu Amooru Gangaiah and Chinna Gangi Reddy Nallagondu	
3.1 Introduction	69
3.2 Synthetic strategies of pyridine based heterocycles	70
3.2.1 Synthesis of pyridine nucleus	70
3.2.2 Synthesis of 2-aminopyridines and 2-amino-3-cyano pyridines	73
3.2.3 Synthesis of pyridinium salts	76
3.2.4 Synthesis of imidazopyridines	78
3.2.5 Synthesis of pyrazolopyridines	81
3.2.6 Synthesis of furopyridines	83
3.3 Therapeutic potential of pyridine scaffolds as anti-Alzheimer's agents	85
3.3.1 Cholinesterase inhibitors	86
3.3.2 A $\beta$ aggregation inhibitors	89
3.3.3 Secretase Inhibitors	95
3.3.4 Tau aggregation inhibitors	98
3.3.5 Glycogen synthase kinase- $3\beta$ inhibitors	100
3.3.6 MAO-B inhibitors 3.3.7 Neuroprotective agents	101 102
3.3.8 Adenosine $A_1$ and $A_{2A}$ receptor antagonists	104
3.3.9 Selective muscarinic M1 subtype activation	105
3.3.10 Phosphodiesterase (PDE) inhibitor	106
3.3.11 Nicotinic acetylcholine receptor (nAChRs) ligands	106
3.3.12 Multitarget directed ligands (MTDLs)	107
3.4 Conclusions	110
References	112
4. Design, synthesis, and in vitro anticancer activity of thiophene substituted	
pyridine derivatives	
Vinayak Adimule, Basappa C Yallur and Sheetal Batakurki	
4.1 Introduction	127
4.2 Materials and characterization	129
4.2.1 Synthesis of 2-(5-bromothiophen-2-yl) pyridin-3-amine (Compound 2, Step 1)	130
4.2.2 Synthesis of 2-(5-aminothiophen-2-yl) pyridin-3-amine (Compound 3, Step 2)	130

Contents	vii
4.2.3 Synthesis of substituted N-[2-(5-aminothiophen-2-yl) pyridin-3-yl] benzamide 4 (a-h)	
(Compound 4, Step 3)	130
4.2.4 Synthesis of substituted N-[5-(3-benzamidopyridin-2-yl) thiophen-2-yl] benzamide	
(Compound 5, Step 4)	130
4.3 Purification of the compounds	130
4.4 Analytical characterization	131
4.4.1 <sup>1</sup> H-NMR, <sup>13</sup> CMR, and LCMS spectroscopic characterization data	131
4.4.2 Substituted N-[2-(5-aminothiophen-2-yl) pyridin-3-yl] benzamide (Compound 4 (a–h))	131
4.4.3 Substituted N-[5-(3-benzamidopyridin-2-yl)thiophen-2-yl]benzamide (Compound 5 (a–h))	133
4.5 In vitro anticancer activity of the compounds (5 a–h)	135
4.5.1 MTT assay	135
4.6 Anticancer activity	135
4.6.1 Preparation of the cell culture and fixation	135 136
4.7 Biological properties 4.7.1 Cytotoxic activities	136
4.7.2 Molecular modeling and computational characteristics of the synthesized compounds	137
4.8 Conclusion	139
Acknowledgments	140
Authors Contributions	140
Conflict of Interest	140
Data Availability	140
Funding	140
References	140
5. The role of pyridine derivatives on the treatment of some complex diseases: A review	
Xolani Henry Makhoba	
5.1 Introduction	143
5.2 Pyridines in general	144
5.3 Synthesis of pyridines derivatives	145
5.4 Life cycle of the malaria parasites	147
5.5 Pyridine containing drugs for malaria treatment	147
5.6 Cancer	147
5.7 Diabetes	151
5.8 Conclusion and future perspectives	152
Acknowledgments	154
Conflict of Interest	154
References	154
6. Pyridines in Alzheimer's disease therapy: Recent trends and advancements	
Puja Mishra, Souvik Basak, Arup Mukherjee and Balaram Ghosh	
6.1 Introduction	159
6.1.1 Etiology of Alzheimer's disease-cholinergic hypothesis	160
6.1.2 $\beta$ -amyloid hypothesis	160
6.1.3 BACE-1 (β-amyloid cleaving enzyme-1) role in AD	162
6.1.4 Metal chelators in AD	162

viii	Contents

· · · · · · · · · · · · · · · · · · ·	
6.2 Pyridine and its role in prevention of Alzheimer's disease	163
6.2.1 Pyridine—a short synopsis on its chemistry	163
6.2.2 Role of pyridines in AChE (acetylcholine esterase) inhibition	164
6.2.3 Role of pyridine in preventing $\beta$ -amyloid aggregation	165
6.2.4 Role of pyridine as BACE-1 (beta-site amyloid precursor protein cleaving enzyme)	
inhibitors	170
6.2.5 Role of pyridine as metal chelators	174
6.3 Synthetic routes of some pyridine derivatives used in AD	178
6.3.1 Synthesis of imidazo [1,5a] pyridine carboxylic acids derivative	178
6.3.2 2,6-disubstituted pyridine	181
6.3.3 Pyrrolo aminopyridine	181
6.3.4 Bis-1,2,4-triazole/thiosemicarbazide	181
6.4 Toxicological manifestations of pyridine	182
6.5 Molecular modeling and computational simulation of pyridine in AD	182
6.6 Pyridine in AD research (marketed drugs as well as preclinical trial drug having pyridine)	183
6.7 Conclusion	184
References	184
7. Pyridine derivatives as anti-Alzheimer agents	
Babita Veer and Ram Singh	
David Feet did Fall onga	
7.1 Introduction	189
7.2 Target-based evaluation of pyridine derivatives as anti-Alzheimer agents	190
7.2.1 Pyridine derivatives as cholinesterase inhibitors	190
7.2.2 Pyridine derivatives as anti-β amyloid aggregates	194
7.2.3 Pyridine derivatives as BACE1 inhibitor	196
7.2.4 Pyridine derivatives as metal chelators	199
7.2.5 Pyridine derivatives for miscellaneous targets	199
7.3 Summary	202
References	202
8. Role of pyridines as enzyme inhibitors in medicinal chemistry	
Khalid Mohammed Khan, Syeda Shaista Gillani and Faiza Saleem	
8.1 General introduction	207
8.2 Marketed drugs based on pyridine nucleus	208
8.3 Synthesis of pyridine derivatives	212
8.4 Medicinal importance of pyridine	214
8.4.1 Anticancer activity	215
8.4.2 Cholinesterase inhibition activity	221
8.4.3 Antidiabetic activity	225
8.4.4 Urease inhibitory activity	232
8.4.5 Antioxidant activities	234
8.4.6 Antiinflammatory activity	235
8.4.7 Antimicrobial activity	236
References	245
	213

Contents ix

# 9. Contemporary development in the synthesis and biological applications of pyridine-based heterocyclic motifs

	troduction	253
	nthesis of pyridine	254
	9.2.1 Hantzsch pyridine synthesis	254
	9.2.2 Baeyer pyridine synthesis	254
	9.2.3 Kröhnke pyridine synthesis	255
	9.2.4 Katrizky pyridine synthesis	256
	reen approach for the synthesis of pyridine	256
	9.3.1 Ultrasound-assisted green synthesis	256
	9.3.2 Microwave-assisted synthesis of pyridine	259
,	nthesis and antimicrobial activity of some pyridine derivatives	259
	nthesis and antitubercular activity of some pyridine derivatives	264
	nthesis and anticancer activity of some pyridine derivatives	275
-	nthesis and anti-inflammatory activity of some pyridine derivatives	285
	nthesis and antimalarial activity of some pyridine derivatives	288
	rnthesis and anti-infective activity of some pyridine derivatives	292
	onclusion	293
	raphical conclusion	294
	vledgments	295
Referen	ces	295
	10. Synthesis of pyridine derivatives using multicomponent reactions	
	Shah Imtiaz, Bhoomika Singh and Md. Musawwer Khan	
	troduction	299
	portance of pyridine and its derivatives	300
	assification of pyridines	302
	0.3.1 Aromatic	302
	0.3.2 Nonaromatic	303
	ulticomponent reactions: its importance and green features	305
	enthesis of simple pyridine derivatives using multicomponent reactions	306
	0.5.1 Ammonium acetate as a source of nitrogen to pyridine ring	306
	0.5.2 Amine group as a source of nitrogen to pyridine ring	313
	0.5.3 Malononitrile as a source of nitrogen to pyridine ring	316
	0.5.4 Miscellaneous	322
	onclusion	324
	vledgments	324
Referen	ces	324
1	1. Recent green synthesis of pyridines and their fused systems catalyzed by	
-	nanocatalysts	
	Amira Elsayed Mahmoud Abdallah	

11.1 Introduction 331

X Con	tents
-------	-------

11.2 Recent green synthesis of polysubstituted pyridines by using heterogeneous nanocatalyst systems 11.2.1 Multicomponent synthesis of 2-amino-3-cyano pyridines by using various heterogeneous	332
nanocatalysts	332
11.2.2 Different heterogeneous nanocatalysts catalyzed the multicomponent synthesis	
of 1,4-dihydropyridines (1,4-DHPs)	340
11.2.3 Preparation of 2,4,6-triarylpyridine derivatives via various heterogeneous nanocatalysts	346
11.2.4 Various heterogeneous nanocatalysts catalyzed the synthesis of pyridine dicarbonitriles	348
11.2.5 Nanocatalytic activity of Cu/NCNTs catalyst for the synthesis of pyridine derivatives	350
11.3 Recent green synthesis of some selected fused heterocyclic-pyridine derivatives by using	
heterogeneous nanocatalyst systems	350
11.3.1 Recent green synthesis of pyrazolo[3,4-b]pyridine derivatives under various nanocatalysts	352
11.3.2 Recent green synthesis of pyridopyrimidine derivatives by using different nanocatalysts	362
11.3.3 Eco-benign approach for the synthesis of thiazolo[4,5-b]pyridine-6- carbonitrile derivatives	
via MgO nanocatalyst	367
11.3.4 Synthesis of 3-iminoaryl-imidazo[1,2-a]pyridines via manganese Schiff-base complex	
immobilized on chitosan-coated Fe <sub>3</sub> O <sub>4</sub> (Fe <sub>3</sub> O <sub>4</sub> @CSBMn)	367
11.4 Conclusion	368
References	368
12. Pyridine ring as an important scaffold in anticancer drugs	
Amr Elagamy, Laila K. Elghoneimy and Reem K. Arafa	
12.1 Introduction	375
12.1 Introduction 12.2 Pyridine-containing APIs in clinical use for treatment of cancer	376
12.2.1 Abemaciclib	376
12.2.2 Abiraterone acetate	378
12.2.3 Acalabrutinib	379
12.2.4 Alpelisib	381
12.2.5 Apalutamide	382
12.2.6 Axitinib	383
12.2.7 Enasidenib	385
12.2.8 Imatinib	385
12.2.9 Ivosidenib	387
12.2.10 Neratinib	388
12.2.11 Nilotinib	388
12.2.12 Palbociclib	390
12.2.13 Pexidartinib	391
12.2.14 Regorafenib	393
12.2.17 Regolatelilo 12.2.15 Ribociclib	393
12.2.16 Selpercatinib	394
12.2.17 Sonidegib	395
12.2.17 Sondegio	396
12.2.19 Vismodegib	398
References	399

Contents	X

# 13. Recent developments in the synthesis of pyridine analogues as a potent anti-Alzheimer's therapeutic leads

Aluru Rammohan, Baki Vijaya Bhaskar and Grigory V. Zyryanov

13.1 Introduction	411
13.2 Role of pyridine in drug discovery	414
13.3 Pyridine analogues as Alzheimer's disease (AD) drug agents	415
13.3.1 Simple pyridine analogues	416
13.3.2 Bipyridine analogues	419
13.3.3 Nicotine analogues	420
13.3.4 Chromanone and iso-chromanone cohesive pyridine analogues	421
13.3.5 Benzofuran–pyridine analogues	422
13.3.6 Imidazole-pyridine analogues	424
13.3.7 Pyrazole–pyridine analogues	425
13.3.8 Triazole-pyridine analogues	427
13.3.9 Carbazole–pyridine analogues	429
13.3.10 Tacrine analogues	430
13.4 Structure–activity relationship studies (SARs)	434
13.5 Clinical approaches	436
13.6 Summary	436
Acknowledgments	438
References	438
14. Pyridine-based probes and chemosensors	
Pawan Kumar, Bindu Syal and Princy Gupta	
14.1 Introduction	445
14.2 Pyridine-based colorimetric chemosensors	448
14.2.1 Pyridine–pyrazole chemosensors	448
14.2.2 Pyridine–phenol chemosensors	449
14.2.3 Pyridine–carbohydrazide chemosensors	452
14.2.4 Lansopyrazole chemosensors	453
14.2.5 Naphthyl-pyridine chemosensors	453
14.2.6 Pyridine–boron chemosensors	454
14.2.7 Hydrazinyl–pyridine chemosensors	454
14.2.8 Triarylpyridine chemosensors	455
14.2.9 Pyridine–Schiff base chemosensors	455
14.2.10 Pyridine–thiourea chemosensors	456
14.2.11 Pyridine–phthalimide chemosensors	457
14.2.12 Pyridine–hydrazone chemosensors	457
14.2.13 Dipicolinimidamide chemosensors	457 450
14.3 Pyridine-based fluorescent chemosensors	458
14.3.1 Pyridine–carboxamide chemosensors	458
14.3.2 Pyridine–rhodamine chemosensors	460
14.3.3 Pyridine–Schiff base chemosensors	463
14.3.4 Bi/terpyridine chemosensors	466
14.3.5 Pyridine-BODIPY (4,4-difluoro-4-borato-3a,4a-diaza-s-indacene) chemosensors	469 470
17. J.O. I VHOIDE-DVIZZOIE CHEMOSEBSOIS	+/0

	14.3.7 Pyridine–imidazole chemosensors	474
	14.3.8 Pyridine–thiazole chemosensors	476
	14.3.9 Pyridine-hydrazone chemosensors	476
	14.3.10 Pyridine–coumarin chemosensors	477
	14.3.11 Pyridine-based other chemosensors	478
14.4	Pyridine-based dual-mode chemosensors	480
	14.4.1 Pyridine–carboxamide chemosensors	480
	14.4.2 Pyridine–rhodamine chemosensors	482
	14.4.3 Pyridine–Schiff base chemosensors	485
	14.4.4 Pyridine–BODIPOY chemosensors	486
	14.4.5 Pyridine–imidazole chemosensors	487
	14.4.6 Pyridine–thiazole chemosensors	489
	14.4.7 Pyridine–amine chemosensors	490
	14.4.8 Pyridine-based some other chemosensors	491
	Conclusions and future prospects	493
	nowledgments	493
Ketei	rences	493
	15. Recent advances in catalytic synthesis of pyridine derivatives	
	Morteza Torabi, Meysam Yarie, Saeed Baghery and Mohammad Ali Zolfigol	
	Introduction	503
	Basic catalysts	505
	Acidic catalysts	513
	Ionic liquids and molten salts	517
15.5	Transition metal catalysis	520
	15.5.1 Cu catalysis	520
	15.5.2 Fe catalysis	525
	15.5.3 Pd catalysis	527
	15.5.4 Ru catalysis	527
	15.5.5 Ag catalysis	530
	15.5.6 Rh catalysis	535
	15.5.7 Ni catalysis	537
	15.5.8 Sn catalysis	538
	15.5.9 Co catalysis	539 540
	15.5.10 Zr catalysis	540 540
	15.5.11 Mn catalysis	540 541
	15.5.12 Mg catalysis	541
	15.5.13 Al catalysis	541 542
15 6	15.5.14 I <sub>2</sub> catalysis	542
15.0	Heterogeneous catalytic systems  15.6.1 MOE head between actalytic	547
	15.6.1 MOF-based heterogeneous catalysts	547
	15.6.2 Nanomagnetic catalysis	548 559
15 7	15.6.3 Silica-supported catalysts	
19.1	Organocatalysis 15.7.1 Solid acids	561 563
		563
	15.7.2 Carbon nanotube-supported catalysts	564
	15.7.3 Miscellaneous	J04

Contents	xiii
15.8 Conclusion	569
Acknowledgments	569
References	570
16. Pyridine as a potent antimicrobial agent and its recent disc	coveries
Nitish Kumar, Harmandeep Kaur, Anchal Khanna, Komalpreet Kaur, Jatinder Vir Singh, Sarabjit Kau Preet Mohinder Singh Bedi, Balbir Singh	r,
16.1 Introduction	581
16.2 Pyridine as antimicrobial agents	583
16.2.1 Compounds containing oxygen in the heterocyclic nucleus	583
16.2.2 Compounds containing nitrogen in the heterocyclic nucleus	584
16.2.3 Compounds containing more than one hetero atom in heterocyclic ring	589
16.2.4 Organometallic	596
16.2.5 Miscellaneous	597
16.3 Pharmacophoric features	599
16.4 Conclusion	601
16.5 Authors contribution	601
References	601
17. Synthesis of pyridine derivatives for diverse biological activity pro	ofiles: A review
,	605
17.1 Introduction	605
17.2 Synthetic strategy	607
17.3 Biological activity profiles	612
17.3.1 Antimicrobial activities	612
17.3.2 Anticancer activity	613 615
17.3.3 Antidiabetic activity	616
17.3.4 Antimalarial agents	
17.3.5 Antituberculosis	616
17.3.6 Anti-inflammatory activity	617
17.3.7 Antihypertensive agents	617
17.3.8 Antiamoebic agents	618
17.3.9 Antiarhythmatic activity	618
17.3.10 Enzyme inhibition	619
17.4 Conclusion	619
Acknowledgment References	620
References	620
Index	625

6

# Pyridines in Alzheimer's disease therapy: Recent trends and advancements

Puja Mishra<sup>a</sup>, Souvik Basak<sup>a</sup>, Arup Mukherjee<sup>b</sup> and Balaram Ghosh<sup>c</sup>

<sup>a</sup>Dr. B.C. Roy College of Pharmacy & Allied Health Sciences, Durgapur, West Bengal, India <sup>b</sup>Department of Biotechnology, Maulana Abul Kalam Azad University of Technology, West Bengal, India <sup>c</sup>Epigenetic Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Hyderabad, Telangana, India

# 6.1 Introduction

Alzheimer's is named after a German Psychiatrist Alois Alzheimer while performing a histopathological study of his patient (Auguste Deter) brain, who died suffering from dementia, known as a physical disease that affects the brain [1]. Further, this was defined as a progressive neurodegenerative disorder, characterized by gradual loss of cholinergic neurons and accumulation of  $\beta$ -amyloid protein in the brain areas like the cortex and hippocampus. The disease onset starts with short-term memory impairment that gradually progresses to complete loss of cognitive function, weak performance of activities of daily life, loss of logical thoughts, emotional disturbances and erratic mood fluctuations, paranoia and hallucinations, and ultimately death [2,3].

The main causes of Alzheimer's are age-related factors, genetic, mutation, health, lifestyle, and environmental factors. However, the exact cause of Alzheimer is not very clearly understood. Early onset of Alzheimer may be due to genetic mutation. Late-onset Alzheimer may be due to several changes in the brain which occur in decades. Mostly this disease is seen in the elderly due to atrophy (shrinking) in various regions of the brain. The increased levels of metals such as Fe, Al, and Hg in the brain generate unstable reactive species like free radicals, increased lipid peroxidation and unsaturated fatty acid content, DNA oxidation, and decreased cytochrome C oxidase. Mutations in critical regions of amyloid precursor